deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT03896295

An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis

An Open-label Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis

Sponsor: Momenta Pharmaceuticals, Inc.

Interventions M281
Updated 21 times since 2019 Last updated: Jun 7, 2023 Started: Aug 6, 2019 Primary completion: Dec 9, 2020 Completion: Dec 9, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study was originally halted due to the COVID-19 pandemic. The study was later terminated prematurely as the participants will have the option to enter into an open-label extension portion of a planned future study. It was not due to safety concerns.

Other terminated trials from Momenta Pharmaceuticals, Inc.

More terminations from Momenta Pharmaceuticals, Inc.

This PHASE2 trial investigates Generalized Myasthenia Gravis and is currently terminated or withdrawn. Momenta Pharmaceuticals, Inc. leads this study, which shows 21 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Sep 2019 · 4 months · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Nov 2020 · 6 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jun 2021 · 3 months · monthly snapshot~Jun 2021 – ~Dec 2021 · 6 months · monthly snapshot~Dec 2021 – ~Mar 2022 · 3 months · monthly snapshot~Mar 2022 – ~Jul 2023 · 16 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

21 versions recorded
  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Jul 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Mar 2022 — Jul 2023 [monthly]

    Terminated PHASE2

Show 16 earlier versions
  1. Dec 2021 — Mar 2022 [monthly]

    Terminated PHASE2

  2. Jun 2021 — Dec 2021 [monthly]

    Terminated PHASE2

  3. Mar 2021 — Jun 2021 [monthly]

    Terminated PHASE2

    Status: SuspendedTerminated

  4. Jan 2021 — Mar 2021 [monthly]

    Suspended PHASE2

  5. Nov 2020 — Jan 2021 [monthly]

    Suspended PHASE2

  6. May 2020 — Nov 2020 [monthly]

    Suspended PHASE2

    Status: RecruitingSuspended

  7. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE2

  8. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE2

  9. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE2

  10. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE2

  11. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  12. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  13. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  14. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet RecruitingRecruiting

  15. May 2019 — Sep 2019 [monthly]

    Not Yet Recruiting PHASE2

  16. Apr 2019 — May 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Momenta Pharmaceuticals, Inc.
Data source: Momenta Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .